US EditionACTG Presents Study at CROI Demonstrating Increased Risk of Obesity and Cardiometabolic Disease After Switch to Integrase Inhibitor-Containing Regimen
Summary by Financial Post
9 Articles
9 Articles
All
Left
8
Center
Right
1
Orangeville+8 Reposted by 8 other sources
ACTG Presents Study at CROI Demonstrating Increased Risk of Obesity and Cardiometabolic Disease After Switch to Integrase Inhibitor-Containing Regimen
LOS ANGELES, March 08, 2025 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented data demonstrating that switching to an integrase inhibitor-based antiretroviral regimen increased the risk of weight gain and…
·Orangeville, Canada
Read Full ArticleCoverage Details
Total News Sources9
Leaning Left8Leaning Right1Center0Last UpdatedBias Distribution89% Left
Bias Distribution
- 89% of the sources lean Left
89% Left
L 89%
11%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
